Organovo Holdings (Seite 69)
eröffnet am 23.10.12 18:24:31 von
neuester Beitrag 11.05.22 09:20:03 von
neuester Beitrag 11.05.22 09:20:03 von
Beiträge: 1.673
ID: 1.177.413
ID: 1.177.413
Aufrufe heute: 0
Gesamt: 314.204
Gesamt: 314.204
Aktive User: 0
ISIN: US68620A2033 · WKN: A2QA6Q · Symbol: 4OR1
0,9260
EUR
-2,01 %
-0,0190 EUR
Letzter Kurs 25.04.24 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 0,5250 | +19,08 | |
| 5,8900 | +17,80 | |
| 12,800 | +17,43 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 3,0400 | -19,95 | |
| 1,9500 | -25,14 | |
| 0,5121 | -30,80 |
Beitrag zu dieser Diskussion schreiben
Feedback
alles am Laufen würde ich sagen
Ausbruch -->click https://www.tradingview.com/x/NaVZS05s/ gelungen….
werde jetzt bei dem Weg nach oben immer wieder bei Schwäche hinzu akkumulieren.
Das wird eine Langläufer-Rentenpapier
Gruss S.
Ausbruch -->click https://www.tradingview.com/x/NaVZS05s/ gelungen….
werde jetzt bei dem Weg nach oben immer wieder bei Schwäche hinzu akkumulieren.
Das wird eine Langläufer-Rentenpapier
Gruss S.
Antwort auf Beitrag Nr.: 52.563.551 von Schaeffi am 07.06.16 22:02:19Hallo,
Sehr solide und die Aussichten für 2017 mit 4 -6 Mio liegen sogar leicht über meiner persönlichen Umsatzprognose von 3,5 Mio.
Und der Nierentest scheint das erwartete Kundeninteresse auszulösen!
Bin gespannt auf den gleich folgenden Webcast
Organovo Announces Fiscal Fourth-Quarter and Full-Year 2016 Results; Company Issues Full-Year Fiscal 2017 Outlook
SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today reported financial results for the fiscal fourth quarter of 2016, issued its full-year fiscal 2017 outlook and affirmed its long-range guidance. Net loss was $8.4 million, or $0.09 per share, for the fiscal fourth quarter of 2016, as compared to $7.8 million, or $0.10 per share, for the fiscal fourth quarter of 2015.
Organovo reported fiscal fourth-quarter total revenue of $0.5 million, which consisted primarily of collaborations and product and service revenue. Total revenue increased 105 percent versus the comparable period of fiscal 2015 and 67 percent versus the fiscal third quarter of 2016. Collaborations revenue, which primarily represents revenue from the Company’s research agreements with L’Oreal USA and Merck & Co., increased by $0.4 million from the year-ago period.
“Fiscal 2016 was a rewarding year for Organovo, as we achieved many of our key operating and scientific targets,” said Keith Murphy, CEO, Organovo. “We issued our outlook today for fiscal 2017 total revenue, which reflects meaningful growth as we drive customer adoption of our liver product and reach important milestones in our research collaborations and partnerships. We also continue to penetrate the global Top 25 pharmaceutical space, having recently added one new customer to bring our total to five with this leading group. Repeat agreements remain strong, as evidenced by the fact that we’re now on a third contract with one of our earliest global Top 25 pharma customers.”
Murphy continued, “As we look ahead to fiscal 2017, we’re focused on a few key objectives including accelerated liver tissue revenue growth, initiation of commercial contracting for our kidney product, advancement of our skin model with L’Oreal and sharing preliminary results from our work with multiple tissue types in the therapeutic tissues space. Specifically, we’re moving from functional validation to a customer ‘early-access’ program with our kidney product, and are seeing strong interest from about a dozen potential customers. In all, we’re expanding our product portfolio and diversifying our revenue profile in the preclinical safety and efficacy and disease modeling markets.”
Murphy concluded, “Our ability to grow in fiscal 2017 and beyond is rooted in serving attractive and growing markets with critical unmet needs, our leadership position in the 3D bioprinting space and an exceptional IP portfolio around our technology platform and scientific work. We’re poised to change the shape of life science research and transform medical care.”
Full-Year Fiscal 2016 Organovo Business Highlights
For the full year, Organovo reported net loss of $38.6 million, or $0.43 per share, as compared to net loss of $30.1 million, or $0.38 per share, for fiscal 2015. The Company reported fiscal 2016 total revenue of $1.5 million, which was up 160% from the year-ago period. Total revenue included $0.8 million of product and service revenue and $0.7 million of revenue related to collaborations and grants.
Fourth-Quarter Organovo Business Highlights
Revenue
Product and service revenue was $0.1 million, down 33 percent from the prior-year period, largely driven by the timing of revenue recognition for the Company’s exVive3D Human Liver Tissue research services contracts. As the Company previously stated, certain milestones for revenue recognition from a large customer are expected in early fiscal 2017 rather than late fiscal 2016, reflecting the need for this customer to finalize aspects of its work plan.
Collaborations revenue totaled $0.4 million, primarily supported by a milestone achievement from the Company’s agreement with L’Oreal USA to develop the skin tissue model.
Operating Expenses
Selling, general and administrative expenses decreased 3 percent from the prior-year period to $4.4 million, primarily due to lower employee related costs and non-cash share-based compensation expense.
Research and development costs grew 25 percent year-over-year to $4.5 million, reflecting increased employee related costs and lab supplies.
Liquidity & Capital Resources
The Company ended the fiscal fourth quarter with a cash and cash equivalents balance of $62.1 million. Organovo’s net cash utilization(1) during the period was $7.9 million. The Company’s net cash utilization for the full-year fiscal 2016 was $31.5 million, lower than the expected net cash utilization rate of between $32 million and $34 million.
Working capital was $59.2 million to end the fiscal fourth quarter compared to $46.5 million in the prior-year quarter.
Fiscal-Year 2017 Outlook
The Company issued its full-year fiscal 2017 outlook for total revenue, net cash utilization and initiating of commercial contracting for its kidney tissue product. The Company expects:
Total revenue of between $4 million and $6 million for fiscal-year 2017. Fiscal 2016 total revenue was $1.5 million.
Net cash utilization of between $32.5 million and $36.5 million for fiscal-year 2017. The Company had a cash and cash equivalents balance of $62.1 million for its fiscal year ended March 31, 2016.
Initiation of commercial contracting for its kidney tissue product in the calendar third quarter of 2016.
Fiscal-Year 2017 Outlook
(June 2016)
Fiscal-Year 2017
Total Revenue $4 million - $6 million
Net Cash Utilization $32.5 million - $36.5
million
Initiation of Commercial
Contracting for Kidney Tissue Calendar Third Quarter
of 2016
Long-Range Outlook
The Company affirmed its long-range outlook for potential revenue from its liver tissue product. The Company continues to expect:
As it penetrates the toxicology market, Organovo’s exVive3D Human Liver Tissue and service will grow into the tens of millions in annual revenue, and has $100 million+ revenue potential in the future (inside of a total addressable market of over $1 billion).
Net Cash Utilization Definition
(1) In addition to disclosing financial results that are determined in accordance with U.S. GAAP, the Company provides net cash utilization as a supplemental measure to help investors evaluate the Company’s fundamental operational performance. The Company defines net cash utilization as the change in the amount of cash and cash equivalents at the beginning of the reporting period as compared to the end of the reporting period, excluding financing activities (which would include proceeds from the sale of common stock and the exercise of warrants and stock options). Net cash utilization is an operational measure that should be considered in addition to our results prepared in accordance with U.S. GAAP. This operational measure should not be considered as a substitute for, or superior to, U.S. GAAP results. The Company believes net cash utilization is a relevant and useful operational measure because it provides information regarding our cash utilization rate. Management uses net cash utilization to manage the business, including in preparing its annual operating budget, financial projections and compensation plans. The Company believes that net cash utilization is also useful to investors because similar measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies in similar industries. However, there is no standardized measurement of net cash utilization, and net cash utilization as the Company presents it may not be comparable with similarly titled operational measures used by other companies. Due to these limitations, the Company’s management does not view net cash utilization in isolation but also uses other measurements, such as cash used in operating activities and revenues to measure operating performance.
Gruß, Phase
Sehr solide und die Aussichten für 2017 mit 4 -6 Mio liegen sogar leicht über meiner persönlichen Umsatzprognose von 3,5 Mio.
Und der Nierentest scheint das erwartete Kundeninteresse auszulösen!
Bin gespannt auf den gleich folgenden Webcast
Organovo Announces Fiscal Fourth-Quarter and Full-Year 2016 Results; Company Issues Full-Year Fiscal 2017 Outlook
SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today reported financial results for the fiscal fourth quarter of 2016, issued its full-year fiscal 2017 outlook and affirmed its long-range guidance. Net loss was $8.4 million, or $0.09 per share, for the fiscal fourth quarter of 2016, as compared to $7.8 million, or $0.10 per share, for the fiscal fourth quarter of 2015.
Organovo reported fiscal fourth-quarter total revenue of $0.5 million, which consisted primarily of collaborations and product and service revenue. Total revenue increased 105 percent versus the comparable period of fiscal 2015 and 67 percent versus the fiscal third quarter of 2016. Collaborations revenue, which primarily represents revenue from the Company’s research agreements with L’Oreal USA and Merck & Co., increased by $0.4 million from the year-ago period.
“Fiscal 2016 was a rewarding year for Organovo, as we achieved many of our key operating and scientific targets,” said Keith Murphy, CEO, Organovo. “We issued our outlook today for fiscal 2017 total revenue, which reflects meaningful growth as we drive customer adoption of our liver product and reach important milestones in our research collaborations and partnerships. We also continue to penetrate the global Top 25 pharmaceutical space, having recently added one new customer to bring our total to five with this leading group. Repeat agreements remain strong, as evidenced by the fact that we’re now on a third contract with one of our earliest global Top 25 pharma customers.”
Murphy continued, “As we look ahead to fiscal 2017, we’re focused on a few key objectives including accelerated liver tissue revenue growth, initiation of commercial contracting for our kidney product, advancement of our skin model with L’Oreal and sharing preliminary results from our work with multiple tissue types in the therapeutic tissues space. Specifically, we’re moving from functional validation to a customer ‘early-access’ program with our kidney product, and are seeing strong interest from about a dozen potential customers. In all, we’re expanding our product portfolio and diversifying our revenue profile in the preclinical safety and efficacy and disease modeling markets.”
Murphy concluded, “Our ability to grow in fiscal 2017 and beyond is rooted in serving attractive and growing markets with critical unmet needs, our leadership position in the 3D bioprinting space and an exceptional IP portfolio around our technology platform and scientific work. We’re poised to change the shape of life science research and transform medical care.”
Full-Year Fiscal 2016 Organovo Business Highlights
For the full year, Organovo reported net loss of $38.6 million, or $0.43 per share, as compared to net loss of $30.1 million, or $0.38 per share, for fiscal 2015. The Company reported fiscal 2016 total revenue of $1.5 million, which was up 160% from the year-ago period. Total revenue included $0.8 million of product and service revenue and $0.7 million of revenue related to collaborations and grants.
Fourth-Quarter Organovo Business Highlights
Revenue
Product and service revenue was $0.1 million, down 33 percent from the prior-year period, largely driven by the timing of revenue recognition for the Company’s exVive3D Human Liver Tissue research services contracts. As the Company previously stated, certain milestones for revenue recognition from a large customer are expected in early fiscal 2017 rather than late fiscal 2016, reflecting the need for this customer to finalize aspects of its work plan.
Collaborations revenue totaled $0.4 million, primarily supported by a milestone achievement from the Company’s agreement with L’Oreal USA to develop the skin tissue model.
Operating Expenses
Selling, general and administrative expenses decreased 3 percent from the prior-year period to $4.4 million, primarily due to lower employee related costs and non-cash share-based compensation expense.
Research and development costs grew 25 percent year-over-year to $4.5 million, reflecting increased employee related costs and lab supplies.
Liquidity & Capital Resources
The Company ended the fiscal fourth quarter with a cash and cash equivalents balance of $62.1 million. Organovo’s net cash utilization(1) during the period was $7.9 million. The Company’s net cash utilization for the full-year fiscal 2016 was $31.5 million, lower than the expected net cash utilization rate of between $32 million and $34 million.
Working capital was $59.2 million to end the fiscal fourth quarter compared to $46.5 million in the prior-year quarter.
Fiscal-Year 2017 Outlook
The Company issued its full-year fiscal 2017 outlook for total revenue, net cash utilization and initiating of commercial contracting for its kidney tissue product. The Company expects:
Total revenue of between $4 million and $6 million for fiscal-year 2017. Fiscal 2016 total revenue was $1.5 million.
Net cash utilization of between $32.5 million and $36.5 million for fiscal-year 2017. The Company had a cash and cash equivalents balance of $62.1 million for its fiscal year ended March 31, 2016.
Initiation of commercial contracting for its kidney tissue product in the calendar third quarter of 2016.
Fiscal-Year 2017 Outlook
(June 2016)
Fiscal-Year 2017
Total Revenue $4 million - $6 million
Net Cash Utilization $32.5 million - $36.5
million
Initiation of Commercial
Contracting for Kidney Tissue Calendar Third Quarter
of 2016
Long-Range Outlook
The Company affirmed its long-range outlook for potential revenue from its liver tissue product. The Company continues to expect:
As it penetrates the toxicology market, Organovo’s exVive3D Human Liver Tissue and service will grow into the tens of millions in annual revenue, and has $100 million+ revenue potential in the future (inside of a total addressable market of over $1 billion).
Net Cash Utilization Definition
(1) In addition to disclosing financial results that are determined in accordance with U.S. GAAP, the Company provides net cash utilization as a supplemental measure to help investors evaluate the Company’s fundamental operational performance. The Company defines net cash utilization as the change in the amount of cash and cash equivalents at the beginning of the reporting period as compared to the end of the reporting period, excluding financing activities (which would include proceeds from the sale of common stock and the exercise of warrants and stock options). Net cash utilization is an operational measure that should be considered in addition to our results prepared in accordance with U.S. GAAP. This operational measure should not be considered as a substitute for, or superior to, U.S. GAAP results. The Company believes net cash utilization is a relevant and useful operational measure because it provides information regarding our cash utilization rate. Management uses net cash utilization to manage the business, including in preparing its annual operating budget, financial projections and compensation plans. The Company believes that net cash utilization is also useful to investors because similar measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies in similar industries. However, there is no standardized measurement of net cash utilization, and net cash utilization as the Company presents it may not be comparable with similarly titled operational measures used by other companies. Due to these limitations, the Company’s management does not view net cash utilization in isolation but also uses other measurements, such as cash used in operating activities and revenues to measure operating performance.
Gruß, Phase
California Life Sciences Association Elects Leaders from Merck, Organovo and St. Jude Medical to its Board of Directors
Today, California Life Sciences Association (CLSA) announced its board of directors has appointed three new members: Ben Thorner, Vice President, BD&L and Head of North American Innovation Hubs, Merck; Keith Murphy, Chairman and Chief Executive Officer, Organovo; and Dave Anderson, Vice President, Merger & Acquisition Integration, St. Jude Medical.
California Life Sciences Association (CLSA) is the nation's largest statewide life sciences public policy advocacy and business solutions organization serving more than 750 biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors and service providers.
"We are pleased to welcome these thoughtful leaders from Merck, Organovo and St. Jude Medical to the California Life Sciences Association (CLSA) board of directors," said Sara Radcliffe, President & CEO of California Life Sciences Association (CLSA). "Ben Thorner, Keith Murphy and Dave Anderson will help shape CLSA's agenda and organization goals as we focus on our collective mission of helping grow and foster California's world-leading life sciences sector. These leaders and their respective organizations exemplify the depth and range of CLSA's membership and what we stand for in advancing hope for patients and consumers in California, across our country and around the world." Less
Today, California Life Sciences Association (CLSA) announced its board of directors has appointed three new members: Ben Thorner, Vice President, BD&L and Head of North American Innovation Hubs, Merck; Keith Murphy, Chairman and Chief Executive Officer, Organovo; and Dave Anderson, Vice President, Merger & Acquisition Integration, St. Jude Medical.
California Life Sciences Association (CLSA) is the nation's largest statewide life sciences public policy advocacy and business solutions organization serving more than 750 biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors and service providers.
"We are pleased to welcome these thoughtful leaders from Merck, Organovo and St. Jude Medical to the California Life Sciences Association (CLSA) board of directors," said Sara Radcliffe, President & CEO of California Life Sciences Association (CLSA). "Ben Thorner, Keith Murphy and Dave Anderson will help shape CLSA's agenda and organization goals as we focus on our collective mission of helping grow and foster California's world-leading life sciences sector. These leaders and their respective organizations exemplify the depth and range of CLSA's membership and what we stand for in advancing hope for patients and consumers in California, across our country and around the world." Less
Antwort auf Beitrag Nr.: 52.519.298 von H2OAllergiker am 01.06.16 17:03:40
sind das die Vorboten auf das was uns die Woche Donn. erwartet ??
Organovo Holdings, Inc. Fourth
Quarter Earnings Conference Call
Thursday, June 9, 2016 5:00 p.m. ET
Webcast Presentation
Gruss S.
Ausbruch...
..heute könnte es evtl. so weit sein … > 3USDsind das die Vorboten auf das was uns die Woche Donn. erwartet ??
Organovo Holdings, Inc. Fourth
Quarter Earnings Conference Call
Thursday, June 9, 2016 5:00 p.m. ET
Webcast Presentation
Gruss S.
Fehlausbruch, erstmal weiter Konso? Bullen noch zu schwach.
Trading Spotlight
Ausbruch click-->https://www.tradingview.com/x/r6cIu4aR/
könnte bis auf 3,5 USD gehen, dann Rücksetzer?
könnte bis auf 3,5 USD gehen, dann Rücksetzer?
Antwort auf Beitrag Nr.: 52.396.806 von Schaeffi am 12.05.16 20:57:09Hallo,
mein derzeitiges Aktienuniversum - ich investiere hauptsächlich in US-Werte
zur Zeit aber fast ausschließlich Watchlist; bin parallel nur in wenige Einzelwerte gleichzeitig langfristig investiert- ein hohes Engagement in Wachstumswerte wie ONVO erfordert nicht nur langen Atem sondern natürlich auch ständig hohe Aufmerksamkeit;
Übrigens:
Weiter geht's - wieder - 7 %
Short Interest (Shares Short)
10,818,700
Short Interest Ratio (Days To Cover)
22.4
Short Percent of Float
12.72 %
Short % Increase / Decrease
-7 %
Short Interest (Shares Short) - Prior
http://shortsqueeze.com/?symbol=ONVO&submit=Short+Quote%99
Gruß, Phase
mein derzeitiges Aktienuniversum - ich investiere hauptsächlich in US-Werte
zur Zeit aber fast ausschließlich Watchlist; bin parallel nur in wenige Einzelwerte gleichzeitig langfristig investiert- ein hohes Engagement in Wachstumswerte wie ONVO erfordert nicht nur langen Atem sondern natürlich auch ständig hohe Aufmerksamkeit;
Übrigens:
Weiter geht's - wieder - 7 %
Short Interest (Shares Short)
10,818,700
Short Interest Ratio (Days To Cover)
22.4
Short Percent of Float
12.72 %
Short % Increase / Decrease
-7 %
Short Interest (Shares Short) - Prior
http://shortsqueeze.com/?symbol=ONVO&submit=Short+Quote%99
Gruß, Phase
Antwort auf Beitrag Nr.: 52.396.392 von PhaseDrei am 12.05.16 20:07:18
tja da lob ich mir die Miner
gleichen das Biotechdesaster
bei mir aus
heisst Watchlist nur watch oder auch investiert in die 25?
Zitat von PhaseDrei: Hallo,
Wahrlich kein guter Börsentag heut
Meine aus 25 Werten bestehende US-Watchlist mit Ausnahme von PCLN alle rot:
Und da sind u.a. einige große Biotech-Schwergewichte dabei!
Hmmmmm.......
Gruß, Phase
tja da lob ich mir die Miner
gleichen das Biotechdesaster
bei mir aus
heisst Watchlist nur watch oder auch investiert in die 25?
Antwort auf Beitrag Nr.: 52.396.392 von PhaseDrei am 12.05.16 20:07:18übrigens BM von mir
11/15
11/15
Antwort auf Beitrag Nr.: 52.351.752 von Schaeffi am 05.05.16 18:52:52Hallo,
Wahrlich kein guter Börsentag heut
Meine aus 25 Werten bestehende US-Watchlist mit Ausnahme von PCLN alle rot:
Und da sind u.a. einige große Biotech-Schwergewichte dabei!
Hmmmmm.......
also mal was zur Stimmungsaufhellung
Die neuesten Patente
http://stks.freshpatents.com/Organovo-Inc-nm1.php?archive=20…
2016 dürfte für ONVO vielleicht noch holprig verlaufen aber ab dem nächsten Jahr sehen wir - meiner Meinung nach - Land!
Also, bezüglich der Zahlen und Aussichten (Kontrakte) sollte man Keine Wunder erwarten!
Immer daran denken:
Wichtige Vertriebs-Schlüsselpositionen sind teilweise erst 6 Monate besetzt.
Gruß, Phase
Wahrlich kein guter Börsentag heut
Meine aus 25 Werten bestehende US-Watchlist mit Ausnahme von PCLN alle rot:
Und da sind u.a. einige große Biotech-Schwergewichte dabei!
Hmmmmm.......
also mal was zur Stimmungsaufhellung
Die neuesten Patente
http://stks.freshpatents.com/Organovo-Inc-nm1.php?archive=20…
2016 dürfte für ONVO vielleicht noch holprig verlaufen aber ab dem nächsten Jahr sehen wir - meiner Meinung nach - Land!
Also, bezüglich der Zahlen und Aussichten (Kontrakte) sollte man Keine Wunder erwarten!
Immer daran denken:
Wichtige Vertriebs-Schlüsselpositionen sind teilweise erst 6 Monate besetzt.
Gruß, Phase
Durchsuchen
